Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [ 18 F]FMPEP-d 2 .

Riikka M AjalinHaidar Al-AbdulrasulJouni M TuiskuJussi E S HirvonenTero VahlbergSalla LahdenpohjaJuha O RinneAnna E Brück

Published in: Movement disorders : official journal of the Movement Disorder Society (2022)

Subjects with PD have lower CB1 receptor availability compared with HCs. PD medication increases CB1 receptor toward normal levels. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

positron emission tomography
computed tomography
healthcare
pet imaging
systematic review
randomized controlled trial
binding protein
emergency department